Perforating dermatosis in a patient receiving bevacizumab

Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment

“…In our series, five patients developed APD during treatment with infliximab. Except for telaprevir and indinavir, all drugs implicated in APD to date are biologics; natalizumab, gefitinib, infliximab, etanercept, bevacizumab, sorafenib and erlotinib . Identifying a common pathogenic mechanism is challenging, as all these compounds have different pharmacological targets.…”

Acute and severe acne in a patient treated with bevacizumab

“…12 Accounts of cutaneous reactions to bevacizumab are limited and typically include itching, exfoliative dermatitis, skin dryness, skin discoloration, impaired wound healing, and stomatitis. 1,13 More recently reported cutaneous adverse effects associated with the use of bevacizumab include nonspecific and acneiform skin rash resembling that seen after the administration of EGFR antagonists, 2-6 cutaneous lupus erythematosus, 14 hand eruption, 15 scalp ulceration 16 , perforating dermatosis, 17 and localized skin necrosis of steroid-induced striae distensae 18 (Table 1).…”

Perforating dermatosis in a patient receiving azathioprine

“…Drug-induced maculopapular rashes, with histological findings suggestive of perforating collagenosis, have previously been described in an oncological patient treated with bevacizumab,[7] as well as under other different drugs like sirolimus, penicillamine, gefitinib, indinavir, and sorafenib. [8–11]…”